Figure 4 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Pharmacodynamic effects at cycle 2, day 1. A, Changes in FOXP3 mRNA expression from baseline in on-treatment biopsy samples. B, Correlation between changes in FOXP3 expression in tumor and in blood for patients with paired biopsy samples. C, Changes in FOXP3 expression in the blood of all patients with available data. D, Changes in Ki67+ CD8+ T cells in the periphery. AC, adrenal carcinoma; BOR, best overall response; CC, cervical cancer; GC, gastric cancer; H&N, head and neck carcinoma; HP, hemangiopericytoma; M, melanoma; NE, not evaluable; PD, progressive disease; TC, thyroid cancer; TNBC, triple-negative breast cancer.
Authors: Lillian L. Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez, Guillermo de Velasco, Eduardo Castanon Alvarez, Christos E. Kyriakopoulos, Melissa Johnson, Kaïssa Ouali, Stephen McMorn, Helen K. Angell, Felicia Ng, Shashank Saran, Mahdiye Bayat, Teresa Collins, Archana Roy, Arthur W. Lambert, Song Cho, Neil Miller, Michele Petruzzelli, John Stone, Christophe Massard
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4410339012